Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | UBE2M | P61081 | 4/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28768418 | 0.85 | HSD11B1 (0.53) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL4294205 | 0.84 | HSD11B1 (0.52) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL2962141 | 0.81 | MAPK7 (0.44) | — | |
| SCHEMBL2187632 | 0.78 | HCRTR1 (0.45) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL3060003 | 0.77 | HSD11B1 (0.53) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL2187198 | 0.77 | HSD11B1 (0.44) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL2187636 | 0.77 | HSD11B1 (0.45) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL2186848 | 0.77 | TSHR (0.52) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL2188215 | 0.77 | HCRTR1 (0.45) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B | |
| SCHEMBL2188775 | 0.77 | MGLL (0.53) | HSD11B1MGLLHCRTR2HCRTR1CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267717-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKB2, NFKBIA, NFRKB | HSD11B1 998/4885MGLL 4732/4885HCRTR2 304/4885 |
| US-20100048574-A1 | NOVEL HETEROCYCLIC NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | HSD11B1 830/4885MGLL 4577/4885HCRTR2 4474/4885 |
| US-20100004258-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, IKBKB, NFKB2 | HSD11B1 848/4885MGLL 4611/4885HCRTR2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.